Point72 Asset Management
RVMD icon

Point72 Asset Management’s Revolution Medicines RVMD Stock Holding History

Point72 Asset Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$253K Buy
+2,600
New +$263K ﹤0.01% 3430

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Point72 Asset Management's RVMD Position: Q1 2026 in Review

Point72 Asset Management sold out of Revolution Medicines (RVMD) in Q1 2026, closing a stake of 446,616 shares — an estimated $45.1M sold.

Point72 Asset Management first reported a position in RVMD in Q2 2021 and held it in 8 quarters. The position peaked at $35.6M in Q4 2025. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

  • Point72 Asset Management reported no remaining Revolution Medicines position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 446,616 Revolution Medicines shares in Q1 2026, an estimated $45.1M.
  • Point72 Asset Management first reported a position in Revolution Medicines in Q2 2021 and held it in 8 quarters.
  • Point72 Asset Management's Revolution Medicines position peaked at $35.6M in Q4 2025.
  • 512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.